Log in
NASDAQ:EPZM

Epizyme Stock Forecast, Price & News

$12.81
-0.45 (-3.39 %)
(As of 09/21/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.03
Now: $12.81
$13.04
50-Day Range
$12.00
MA: $12.72
$14.37
52-Week Range
$9.73
Now: $12.81
$27.82
Volume1.51 million shs
Average Volume1.07 million shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Read More
Epizyme logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.80 million
Book Value$3.22 per share

Profitability

Net Income$-170,290,000.00
Net Margins-1,459.72%

Miscellaneous

Employees124
Market Cap$1.30 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$12.81
-0.45 (-3.39 %)
(As of 09/21/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Epizyme (NASDAQ:EPZM) Frequently Asked Questions

How has Epizyme's stock price been impacted by COVID-19?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EPZM stock has decreased by 30.6% and is now trading at $12.81.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Epizyme
.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Epizyme
.

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.02. The biopharmaceutical company had revenue of $2.47 million for the quarter, compared to analyst estimates of $4.67 million. Epizyme had a negative return on equity of 72.65% and a negative net margin of 1,459.72%.
View Epizyme's earnings history
.

What price target have analysts set for EPZM?

8 analysts have issued 1-year price objectives for Epizyme's shares. Their forecasts range from $16.00 to $36.00. On average, they anticipate Epizyme's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 126.4% from the stock's current price.
View analysts' price targets for Epizyme
.

Who are some of Epizyme's key competitors?

What other stocks do shareholders of Epizyme own?

Who are Epizyme's key executives?

Epizyme's management team includes the following people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.11%), Victory Capital Management Inc. (2.26%), FMR LLC (1.98%), Charles Schwab Investment Management Inc. (0.53%), Nuveen Asset Management LLC (0.45%) and Bank of New York Mellon Corp (0.35%). Company insiders that own Epizyme stock include David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme
.

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including Atom Investors LP, Federated Hermes Inc., Rhenman & Partners Asset Management AB, First Trust Advisors LP, AlphaCrest Capital Management LLC, Alps Advisors Inc., Bank of America Corp DE, and Principal Financial Group Inc.. Company insiders that have sold Epizyme company stock in the last year include Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme
.

Which major investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Man Group plc, Greenspring Associates LLC, Vanguard Group Inc., Teacher Retirement System of Texas, Pier Capital LLC, Victory Capital Management Inc., Point72 Asset Management L.P., and California State Teachers Retirement System.
View insider buying and selling activity for Epizyme
.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $12.81.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.30 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 124 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.